Quality-of-life assessment in rheumatoid arthritis

PharmacoEconomics

Volumn 26, Issue 10, 2008, Pages 831-846

  Russell, Anthony S ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Abatacept, therapeutic use; Adalimumab, therapeutic use; Anakinra, therapeutic use; Cost effectiveness; Cost utility; Disease modifying antirheumatics, therapeutic use; Etanercept, therapeutic use; Infliximab, therapeutic use; Quality of life

Indexed keywords

ABATACEPT; ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB;

CLINICAL ASSESSMENT; CLINICAL PRACTICE; DISEASE ACTIVITY; ECONOMIC ASPECT; HEALTH ASSESSMENT QUESTIONNAIRE; HEALTH CARE COST; HUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; SHORT FORM 36;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS AS TOPIC; HEALTH STATUS INDICATORS; HUMANS; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 51949106447     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200826100-00004     Document Type: Review

References (82)

1. Turesson C, O'Fallon WM, Crowson CS, et al. Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis. J Rheumatol 2002 Jan; 29 (1): 62-7
2. Kosinski M, Kujawski SC, Martin R, et al. Health-related quality of life in early rheumatoid arthritis: impact of disease and treatment response. Am J Manag Care 2002 Mar; 8 (3): 231-40
3. Fautrel B, Guillemin F. Cost of illness studies in rheumatic diseases. Curr Opin Rheumatol 2002 Mar; 14 (2): 121-6
4. Allaire SH, Prashker MJ, Meenan RF. The costs of rheumatoid arthritis. Pharmacoeconomics 1994 Dec; 6 (6): 513-22
5. Gremillion RB, van Vollenhoven RF. Rheumatoid arthritis: designing and implementing a treatment plan. Postgrad Med 1998 Feb; 103 (2): 103-6, 10, 18
6. Bansback NJ, Regier DA, Ara R, et al. An overview of economic evaluations for drugs used in rheumatoid arthritis: focus on tumour necrosis factor-alpha antagonists. Drugs 2005; 65 (4): 473-96
7. Raza K, Buckley CE, Salmon M, et al. Treating very early rheumatoid arthritis. Best Pract Res Clin Rheumatol 2006 Oct; 20 (5): 849-63
8. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002 Feb; 46 (2): 328-46
9. The World Health Organization Quality of Life assessment (WHOQOL): position paper from the World Health Organization. Soc Sci Med 1995 Nov; 41 (10): 1403-9
10. Kvien TK, Uhlig T. Quality of life in rheumatoid arthritis. Scand J Rheumatol 2005 Sep-Oct; 34 (5): 333-41
11. US Food and Drug Administration. Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims [online]. Available from URL: http://www.fda.gov/cder/guidance/5460dft.htm. [Accessed 2007 Oct 11]
12. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology: preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995 Jun; 38 (6): 727-35
13. Department of Rheumatology, University Medical Centre. DAS-Score.nl: disease activity score in rheumatoid arthritis [online]. Available from URL: http://www.das-score.nl/www.das-score.nl/index.html [Accessed 2007 Oct 11]
14. Den Broeder AA, Creemers MC, van Gestel AM, et al. Dose titration using the Disease Activity Score (DAS28) in rheumatoid arthritis patients treated with anti-TNF-alpha. Rheumatology (Oxford) 2002 Jun; 41 (6): 638-42
15. Khanna D. Health-related quality of life: a primer with a focus on scleroderma [online]. Available from URL: http://www.sctc-online.org/pdfs/ SCARV3N2.pdf [Accessed 2007 Oct 12]
16. Tsevat J, Weeks JC, Guadagnoli E, et al. Using health-related quality-of-life information: clinical encounters, clinical trials, and health policy. J Gen Intern Med 1994 Oct; 9 (10): 576-82
17. Guillemin F. Functional disability and quality-of-life assessment in clinical practice. Rheumatology (Oxford) 2000 Jun; 39 Suppl. 1: 17-23
18. Lubeck DP. Health-related quality of life measurements and studies in rheumatoid arthritis. Am J Manag Care 2002 Sep; 8 (9): 811-20
19. Lubeck DP. Patient-reported outcomes and their role in the assessment of rheumatoid arthritis. Pharmacoeconomics 2004; 22 (2 Suppl. 1): 27-38
20. Russell AS, Conner-Spady B, Mintz A, et al. The responsiveness of generic health status measures as assessed in patients with rheumatoid arthritis receiving infliximab. J Rheumatol 2003 May; 30 (5): 941-7
21. Coons SJ, Rao S, Keininger DL, et al. A comparative review of generic quality-of-life instruments. Pharmacoeconomics 2000 Jan; 17 (1): 13-35
22. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002 Mar; 21 (2): 271-92
23. de Jong Z, van der Heijde D, McKenna SP, et al. The reliability and construct validity of the RAQoL: a rheumatoid arthritis-specific quality of life instrument. Br J Rheumatol 1997 Aug; 36 (8): 878-83
24. The EuroQol group. A new facility for the measurement of health-related quality of life. Health Policy 1999; 16: 199-208
25. Wyrwich KW, Bullinger M, Aaronson N, et al. Estimating clinically significant differences in quality of life outcomes. Qual Life Res 2005 Mar; 14 (2): 285-95
26. Jaeschke R, Singer J, Guyatt GH. Measurement of health status: ascertaining the minimal clinically important difference. Control Clin Trials 1989 Dec; 10 (4): 407-15
27. Guyatt GH, Osoba D, Wu AW, et al. Methods to explain the clinical significance of health status measures. Mayo Clin Proc 2002 Apr; 77 (4): 371-83
28. Fries JF, Spitz P, Kraines RG, et al. Measurement of patient outcome in arthritis. Arthritis Rheum 1980 Feb; 23 (2): 137-45
29. Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: dimensions and practical applications. Health Qual Life Outcomes 2003 Jun 9; 1 (1): 20
30. Wells GA, Tugwell P, Kraag GR, et al. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol 1993 Mar; 20 (3): 557-60
31. Kosinski M, Zhao SZ, Dedhiya S, et al. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 2000 Jul; 43 (7): 1478-87
32. Hewlett S, Smith AP, Kirwan JR. Measuring the meaning of disability in rheumatoid arthritis: the Personal Impact Health Assessment Questionnaire (PI HAQ). Ann Rheum Dis 2002 Nov; 61 (11): 986-93
33. Fries JF, Ramey DR. 'Arthritis specific' global health analog scales assess 'generic' health related quality-of-life in patients with rheumatoid arthritis. J Rheumatol 1997 Sep; 24 (9): 1697-702
34. Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care 1992 Jun; 30 (6): 473-83
35. McHorney CA, Ware Jr JE, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993 Mar; 31 (3): 247-63
36. PROQUOLID. Patient-reported outcome and quality of life instruments data base home page [online]. Available from URL: http://www.quolid.com [Accessed 2007 Oct 11]
37. Conner-Spady B, Suarez-Almazor ME. Variation in the estimation of quality-adjusted life-years by different preference-based instruments. Med Care 2003 Jul; 41 (7): 791-801
38. The EuroQol Group. EuroQol: a new facility for the measurement of health-related quality of life. Health Policy 1990 Dec; 16 (3): 199-208
39. Brooks R. EuroQol: the current state of play. Health Policy 1996 Jul; 37 (1) 53-72
40. Marra CA, Esdaile JM, Guh D, et al. A comparison of four indirect methods of assessing utility values in rheumatoid arthritis. Med Care 2004; 42 (11): 1125-31
41. Feeny D, Furlong W, Torrance GW, et al. Multiattribute and single-attribute utility functions for the health utilities index mark 3 system. Med Care 2002 Feb; 40 (2): 113-28
42. Horsman J, Furlong W, Feeny D, et al. The Health Utilities Index (HUI): concepts, measurement properties and applications. Health Qual Life Outcomes 2003; 1 (1): 1-13
43. Drummond MF, O'Brien BJ, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford (NY): Oxford University Press, 1997
44. Duru G, Auray JP, Beresniak A, et al. Limitations of the methods used for calculating quality-adjusted life-year values. Pharmacoeconomics 2002; 20 (7): 463-73
45. Meenan RF, Mason JH, Anderson JJ, et al. AIMS2: the content and properties of a revised and expanded Arthritis Impact Measurement Scales Health Status Questionnaire. Arthritis Rheum 1992 Jan; 35 (1): 1-10
46. Cox SR, McWilliams L, Massy-Westropp N, et al. Adaptation of the RAQoL for use in Australia. Rheumatol Int 2007 May; 27 (7): 661-6
47. Tammaru M, McKenna SP, Meads DM, et al. Adaptation of the rheumatoid arthritis quality of life scale for Estonia. Rheumatol Int 2006 May; 26 (7): 655-62
48. Kutlay S, Kucukdeveci AA, Gonul D, et al. Adaptation and validation of the Turkish version of the Rheumatoid Arthritis Quality of Life Scale. Rheumatol Int 2003 Jan; 23 (1): 21-6
49. Russak SM, Croft Jr JD, Furst DE, et al. The use of rheumatoid arthritis health-related quality of life patient questionnaires in clinical practice: lessons learned. Arthritis Rheum 2003 Aug 15; 49 (4): 574-84
50. Proceedings from the sixth biannual conference of the Outcome Measures in Rheumatoid Arthritis Clinical Trials group (OMERACT); 2002 May; Cairns, Australia.
51. Saag KG. OMERACT 6 brings new perspectives to rheumatology measurement research. J Rheumatol 2003 Apr; 30 (4): 639-41
52. Greenwood MC, Hakim AJ, Carson E, et al. Touch-screen computer systems in the rheumatology clinic offer a reliable and user-friendly means of collecting quality-of-life and outcome data from patients with rheumatoid arthritis. Rheumatology (Oxford) 2006 Jan; 45 (1): 66-71
53. Orencia (abatacept) [package insert]. Princeton (NJ): Bristol-Myers Squibb, 2007
54. Rituxan (rituximab) [package insert]. South San Francisco (CA): Biogen Idec Inc. and Genentech, Inc., 2007
55. Kineret (anakinra) [package insert]. Thousand Oaks (CA): Amgen, Inc., 2006
56. Enbrel (etanercept) [package insert]. Thousand Oaks (CA): Immunex Corp., 2006
57. Humira (adalimumab) [package insert]. North Chicago (IL): Abbott Laboratories, 2005
58. Remicade (infliximab) [package insert]. Horsham (PA): Centocor Inc., 2007
59. Maini RN, Breedveld FC, Kalden JR, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004 Apr; 50 (4): 1051-65
60. Han C, Smolen JS, Kavanaugh A, et al. The impact of infliximab treatment on quality of life in patients with inflammatory rheumatic diseases. Arthritis Res Ther 2007; 9 (5): R103 [online]. Available from URL: http://arthritis- research.com/content/pdf/ar2306.pdf [Accessed 2008 Jul 16]
61. Torrance GW, Tugwell P, Amorosi S, et al. Improvement in health utility among patients with rheumatoid arthritis treated with adalimumab (a human anti-TNF monoclonal antibody) plus methotrexate. Rheumatology (Oxford) 2004 Jun; 43 (6): 712-8
62. van der Heijde D, Klareskog L, Singh A, et al. Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial. Ann Rheum Dis 2006 Mar; 65 (3): 328-34
63. Farahani P, Levine M, Gaebel K, et al. Community-based evaluation of etanercept in patients with rheumatoid arthritis. J Rheumatol 2006 Apr; 33 (4): 665-70
64. Kavanaugh A. Anakinra (interleukin-1 receptor antagonist) has positive effects on function and quality of life in patients with rheumatoid arthritis. Adv Ther 2006 Mar-Apr; 23 (2): 208-17
65. Bresnihan B, Cobby M. Clinical and radiological effects of anakinra in patients with rheumatoid arthritis. Rheumatology (Oxford) 2003 May; 42 Suppl. 2: ii22-8
66. Solau-Gervais E, Laxenaire N, Cortet B, et al. Lack of efficacy of a third tumour necrosis factor alpha antagonist after failure of a soluble receptor and a monoclonal antibody. Rheumatology (Oxford) 2006 Sep; 45 (9): 1121-4
67. Keystone EC, Kavanaugh A. What to do with TNF failures. Expert Opin Drug Saf 2005 Mar; 4 (2): 149-55
68. Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol 2002 Feb; 29 (1 Suppl. 2): 2-9
69. Leandro MJ, Cambridge G, Ehrenstein MR, et al. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2006 Feb; 54 (2): 613-20
70. Popa C, Leandro MJ, Cambridge G, et al. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs. Rheumatology (Oxford) 2007 Apr; 46 (4): 626-30
71. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006 Sep; 54 (9): 2793-806
72. Kremer JM, Dougados M, Emery P, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase IIb, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005 Aug; 52 (8): 2263-71
73. Emery P, Kosinski M, Li T, et al. Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of life. J Rheumatol 2006 Apr; 33 (4): 681-9
74. Russell AS, Wallenstein GV, Li T, et al. Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment. Ann Rheum Dis 2007 Feb; 66 (2): 189-94
75. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005 Sep 15; 353 (11): 1114-23
76. Westhovens R, Cole JC, Li T, et al. Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial. Rheumatology (Oxford) 2006 Oct; 45 (10): 1238-46
77. Gabriel S, Drummond M, Maetzel A, et al. OMERACT 6 Economics Working Group report: a proposal for a reference case for economic evaluation in rheumatoid arthritis. J Rheumatol 2003 Apr; 30 (4): 886-90
78. Welsing PMK, Wietske L, Roland FJM, et al. Quality of life and costs for different treatment strategies for rheumatoid arthritis. Exp Rev Neurother 2005; 5 (4): 395-410
79. Doan QV, Chiou CF, Dubois RW. Review of eight pharmaco-economic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis. J Manag Care Pharm 2006 Sep; 12 (7): 555-69
80. Choi HK, Seeger JD, Kuntz KM. A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis. Arthritis Rheum 2000 Oct; 43 (10): 2316-27
81. Azimi NA, Welch HG. The effectiveness of cost-effectiveness analysis in containing costs. J Gen Intern Med 1998 Oct; 13 (10): 664-9
82. Wong JB. Cost-effectiveness of anti-tumor necrosis factor agents. Clin Exp Rheumatol 2004 Sep-Oct; 22 (5 Suppl. 35): S65-70